Assessment of Serum Biomarkers associated with Vedolizumab Therapy Response in Inflammatory Bowel Disease.

被引：0
|
作者：
O'Connell, J. [1 ]
Argue, R. [1 ]
Dunne, M. [2 ]
O'Connell, F. [2 ]
Breslin, N. [3 ]
Cullen, G. [4 ]
Doherty, G. [4 ]
Dunne, C. [1 ]
Hartery, K. [1 ]
Ismail, M. S. [3 ]
MacCarthy, F. [1 ]
McDonagh, P. [1 ]
McKiernan, S. [1 ]
McNamara, D. [3 ]
Mulcahy, H. [1 ,4 ]
O'Connor, A. [3 ]
Ryan, B. [3 ]
Sheridan, J. [4 ]
O'Sullivan, J. [2 ]
Kevans, D. [1 ]
机构：
[1] St James Hosp, Gastroenterol, Dublin, Ireland
[2] Trinity Coll Dublin, Trinity Translat Med Inst, Surg, Dublin, Ireland
[3] Tallaght Univ Hosp, Gastroenterol, Dublin, Ireland
[4] St Vincents Univ Hosp, Gastroenterol, Dublin, Ireland
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P041
引用
收藏
页码：I299 / I299
页数：1
相关论文
共 50 条
  • [1] Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
    Elisa K. Boden
    Donna M. Shows
    Michael V. Chiorean
    James D. Lord
    Digestive Diseases and Sciences, 2018, 63 : 2419 - 2429
  • [2] Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
    Boden, Elisa K.
    Shows, Donna M.
    Chiorean, Michael V.
    Lord, James D.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (09) : 2419 - 2429
  • [3] Vedolizumab response in inflammatory bowel disease. Two years of follow-up
    del Pino Bellido, Pilar
    Belvis Jimenez, Maria
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Saez Diaz, Antonia
    Caunedo Alvarez, Angel
    Arguelles-Arias, Federico
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (07) : 555 - 558
  • [4] Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease.
    Pugliese, Daniela
    Privitera, Giuseppe
    Pizzolante, Fabrizio
    Gasbarrini, Antonio
    Guidi, Luisa
    Armuzzi, Alessandro
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2019, 65 (04) : 280 - 290
  • [5] Predicting Response to Vedolizumab in Inflammatory Bowel Disease
    Meserve, Joseph
    Dulai, Parambir
    FRONTIERS IN MEDICINE, 2020, 7
  • [6] Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
    Vaughn, Byron P.
    Yarur, Andres J.
    Graziano, Elliot
    Campbell, James P.
    Bhattacharya, Abhik
    Lee, Jennifer Y.
    Gheysens, Katherine
    Papamichael, Konstantinos
    Osterman, Mark T.
    Cheifetz, Adam S.
    Cross, Raymond K.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 11
  • [7] Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease
    Batra, Suruchi K.
    Heier, Christopher R.
    Diaz-Calderon, Lina
    Tully, Christopher B.
    Fiorillo, Alyson A.
    van den Anker, John
    Conklin, Laurie S.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (10) : 1597 - 1606
  • [8] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [9] Serum Biomarkers for Inflammatory Bowel Disease
    Chen, Peng
    Zhou, Gaoshi
    Lin, Jingxia
    Li, Li
    Zeng, Zhirong
    Chen, Minhu
    Zhang, Shenghong
    FRONTIERS IN MEDICINE, 2020, 7
  • [10] Changes in serum immune protein profiles following vedolizumab therapy in Inflammatory Bowel Disease
    O'Connell, J.
    O'Connell, F.
    O'Sullivan, J.
    Kevans, D.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I198 - I198
12345